The Molecular Characterization of Hepatitis A Virus Strains Circulating during Hepatitis A Outbreaks in Sao Paulo, Brazil, from September 2017 to May 2019
Carregando...
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
GONZALEZ, Mario P.
COTIA, Andre L. F.
ARANDA, Amanda G. D.
TENORE, Simone B.
MALTA, Fernanda M.
Citação
VIRUSES-BASEL, v.14, n.1, article ID 73, 11p, 2022
Resumo
Outbreaks of hepatitis A may occur in countries of medium and high socioeconomic levels in which the population generally exhibits an increased susceptibility in young adults to this infection if they are not vaccinated against the hepatitis A virus (HAV). In Europe, an outbreak involved approximately 22 European countries with 4475 cases reported from 2016 to 2018; most of them were men who have sex with men (MSM). This outbreak expanded to North and South America, including Brazil, particularly in Sao Paulo city with 1547 reported cases from 2016 to 2019. In the present study, we characterized the HAV strains involved in the acute hepatitis A cases identified in the reference centers of Sao Paulo city during this outbreak. A total of 51 cases with positive anti-HAV IgM were included, 80.4% male, 68.6% of them between 20 and 40 years old and 41.7% MSM. HAV RNA was detected in 92% (47/51) of the cases. Subgenotype IA of HAV was identified and most of the strains were closely related to that isolated in outbreaks that occurred in different European countries in 2016. These results showed the epidemiological relation between these outbreaks and reinforce the need to implement vaccination against hepatitis A for the adult population, particularly for a population with a high-risk behavior.
Palavras-chave
hepatitis A virus, molecular epidemiology, outbreak
Referências
- COREY L, 1980, NEW ENGL J MED, V302, P435, DOI 10.1056/NEJM198002213020804
- Costa-Mattioli M, 2002, J VIROL, V76, P9516, DOI 10.1128/JVI.76.18.9516-9525.2002
- COVISA-Coordenadoria de Vigilancia em Saude Divisao de Vigilancia Epidemiologica, B EPIDEMIOLOGICO SE
- De Oliveira TM, 2020, J MED VIROL, V92, P1343, DOI 10.1002/jmv.25694
- Souto FJD, 2019, VACCINE, V37, P771, DOI 10.1016/j.vaccine.2018.12.054
- European Centre for Disease Prevention and Control, 2018, EP UPD HEP OUTBR EU
- Franco E, 2003, VACCINE, V21, P2224, DOI 10.1016/S0264-410X(03)00137-3
- Freidl GS, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.8.30468
- Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI 10.1021/BK-1999-0734.CH008
- Jacobsen KH, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031716
- Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
- Lima LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102925
- Mello VM, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030281
- Nainan OV, 2006, CLIN MICROBIOL REV, V19, P63, DOI 10.1128/CMR.19.1.63-79.2006
- Ndumbi P, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.33.1700641
- Pereira LMMB, 2021, REV INST MED TROP SP, V63, DOI [10.1590/S1678-9946202163034, 10.1590/s1678-9946202163034]
- Shin EC, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031708
- Vaughan G, 2014, INFECT GENET EVOL, V21, P227, DOI 10.1016/j.meegid.2013.10.023
- Victor JC, 2006, AM J EPIDEMIOL, V163, P204, DOI 10.1093/aje/kwj029
- Wasley A, 2006, EPIDEMIOL REV, V28, P101, DOI 10.1093/epirev/mxj012
- Werber D, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.5.30457